product
ProteinSimple MFI 5000 Series
4 December 2015 | By ProteinSimple
Address the US FDA requirement to characterize and quantify protein aggregates and other particle contaminants sized 1-70 microns in biotherapeutics...
List view / Grid view
Drug Discovery
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
article
Drug Target Review – Issue #4 2015
3 December 2015 | By Drug Target Review
Included in this issue: Biomarkers, Mass Spectrometry, Target Validation, Drug Development, Personalised Medicines, Next-Generation Sequencing, Protein Expression, Companion Diagnostics, and much more...
article
Mass Spectrometry In-Depth Focus 2015
In this Mass Spectrometry In-Depth Focus: Michelle M. Hill from University of Queensland discusses Mass spectrometric and systems biology approaches in drug target discovery, and Nicola Burgess-Brown, Rod Chalk, Claire Strain-Damerell and Pravin Mahajan from the Structural Genomics Consortium look at analysing recombinant proteins by mass spectrometry...
article
The challenges associated with ‘de-risking’ early-stage therapeutic targets
The pharmaceutical industry is searching for novel drug targets that could produce the next generation of ‘first-in-class’ therapeutic agents. The challenge for academia is to identify and translate such targets and to provide starting points and confidence in the underlying science. The aim should be to generate evidence that modulation…
article
Enabling new targets by integrated lead discovery
Progress in the understanding of disease mechanisms provides new opportunities to discover molecules that modulate disease. To capitalise on these opportunities, successful lead discovery strategies need to build on insights into how a cellular phenotype or a target contributes to disease biology. Recent advances in induced pluripotent stem cells (iPSCs),…
news
Boehringer Ingelheim and MD Anderson in pancreatic cancer collaboration
2 December 2015 | By Victoria White
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Centre are to focus on developing new medicines for pancreatic ductal adenocarcinoma...
product
ProteinSimple NanoPro 1000
2 December 2015 | By ProteinSimple
Simple Western™ system for the characterization of post-translational protein modification by the detection of charge isoforms...
news
Heptares and Pfizer to focus on GPCR targets
30 November 2015 | By Victoria White
Heptares and Pfizer have announced they are to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas...
news
Sleeping sickness project passes 20-month milestone
30 November 2015 | By Victoria White
The aim of the project is to design a drug to inhibit a key parasite enzyme involved in the conversion of blood sugars to energy, to be effective in small doses, even on advanced infections, and kill the parasite...
news
UNSW discovery could lead to new Alzheimer’s treatments
27 November 2015 | By Victoria White
Researchers have discovered how connections between brain cells are destroyed in the early stages of Alzheimer’s disease...
news
Pelago and AstraZeneca enter CETSA research collaboration
27 November 2015 | By
Pelago and AstraZeneca will together develop assay formats and applications of the CETSA method relevant across the range of AstraZeneca’s therapeutic areas...
news
ReproCELL acquires Scottish life sciences company Biopta
25 November 2015 | By Victoria White
The transaction, expected to complete next month, is aimed at strengthening ReproCELL’s pharmaceutical industry-targeted drug discovery services...
news
Ablynx and Novo Nordisk in Nanobody drug discovery collaboration
25 November 2015 | By
Ablynx and Novo Nordisk hope to discover and develop novel multi-specific drug candidates using Ablynx's proprietary Nanobody technology...
webinar
Genomic support for target selection and validation in drug development: design of a new genotyping array
22 November 2015 | By Illumina
In this webinar, we focus on the use of microarray technology in drug development...
news
AstraZeneca invests in its Cambridge lead discovery centre
20 November 2015 | By Victoria White
The company has announced three new partnerships that will deliver a collaborative screening platform, space-age robotics, and sound waves that can move liquids...
